相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer
Kristen K. Ciombor et al.
ONCOLOGIST (2018)
Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer
Hiroaki Inoue et al.
BREAST CANCER (2018)
Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN gamma secretion
Bharat K. R. Chaganty et al.
CANCER LETTERS (2018)
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
Robert L. Ferris et al.
CANCER TREATMENT REVIEWS (2018)
Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future
Alex B. Blair et al.
CURRENT PROBLEMS IN CANCER (2018)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal A. Patel et al.
IMMUNITY (2018)
The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer
Xiaoling Xu et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough
Benjamin A. Weinberg et al.
ONCOLOGIST (2018)
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Marc Hilmi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer
Elizabeth Smyth et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Emerging Systemic Therapies for Colorectal Cancer
Christine M. Veenstra et al.
CLINICS IN COLON AND RECTAL SURGERY (2018)
Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice
Ronald Anderson et al.
FRONTIERS IN ONCOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?
Griet Deslypere et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Current therapeutic landscape for advanced gastroesophageal cancers
Anthony Lopez et al.
ANNALS OF TRANSLATIONAL MEDICINE (2018)
Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers
Muhammad Shaalan Beg et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Radiotherapy combination opportunities leveraging immunity for the next oncology practice
Fernanda G. Herrera et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Toshihiro Kudo et al.
LANCET ONCOLOGY (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients
Hyun-Bae Jie et al.
CANCER IMMUNOLOGY RESEARCH (2017)
New Strategies Using Antibody Combinations to increase Cancer Treatment effectiveness
Isabel Corraliza-Gorjon et al.
FRONTIERS IN IMMUNOLOGY (2017)
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient
Alejandro Jimenez-Sanchez et al.
CELL (2017)
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip Gotwals et al.
NATURE REVIEWS CANCER (2017)
Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer
Yuka Inoue et al.
CANCER SCIENCE (2017)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Immunotherapy in colorectal cancer: What have we learned so far?
Maria Sanchez-Castanon et al.
CLINICA CHIMICA ACTA (2016)
Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)
Ewa Maj et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
The immune system and cancer evasion strategies: therapeutic concepts
S. Muenst et al.
JOURNAL OF INTERNAL MEDICINE (2016)
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Celine Boutros et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
Valerie Lee et al.
ONCOLOGIST (2016)
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
Lidia Robert et al.
SEMINARS IN IMMUNOLOGY (2016)
Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model
Shanshan Chen et al.
ONCOLOGY LETTERS (2016)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al.
NATURE COMMUNICATIONS (2016)
Immunological Landscape and Clinical Management of Rectal Cancer
Elisabeth Perez-Ruiz et al.
FRONTIERS IN IMMUNOLOGY (2016)
Radiotherapy: Changing the Game in Immunotherapy
Sandra Demaria et al.
TRENDS IN CANCER (2016)
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
Hyun-Bae Jie et al.
CANCER RESEARCH (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Differences in gastric cancer survival between the US and China
Vivian E. Strong et al.
JOURNAL OF SURGICAL ONCOLOGY (2015)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system
Yago Pico de Coana et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
Association of the Asp312Asn and Lys751Gln polymorphisms in the XPD gene with the risk of non-Hodgkin's lymphoma: evidence from a meta-analysis
Shen Chen et al.
CHINESE JOURNAL OF CANCER (2015)
Immune Response and the Tumor Microenvironment: How They Communicate to Regulate Gastric Cancer
Keunwook Lee et al.
GUT AND LIVER (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Magali Terme et al.
CANCER RESEARCH (2013)
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Yuhui Huang et al.
CANCER RESEARCH (2013)
Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo
S. Yasuda et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer
John H. Strickler et al.
ONCOLOGIST (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
Rajeev K. Shrimali et al.
CANCER RESEARCH (2010)
Hypoxia induces T-cell apoptosis by inhibiting chemokine C receptor 7 expression: the role of adenosine receptor A(2)
Jintang Sun et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2010)
CD28 and CTLA-4 coreceptor expression and signal transduction
Christopher E. Rudd et al.
IMMUNOLOGICAL REVIEWS (2009)
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Takuya Osada et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cancer immunoediting from immune surveillance to immune escape
Ryungsa Kim et al.
IMMUNOLOGY (2007)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation
F Ghiringhelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation
MM Dikov et al.
JOURNAL OF IMMUNOLOGY (2005)
分享论文
